Proton therapy is used to treat a wide range of cancers, but it offers the clearest advantages for tumors near sensitive structures, childhood cancers, and situations where conventional radiation would damage too much healthy tissue. The list includes brain and spinal tumors, head and neck cancers, liver cancer, eye melanomas, skull base tumors, certain sarcomas, and several pediatric cancers. For some of these, proton therapy is the preferred approach. For others, it remains an option with potential benefits that are still being measured against standard radiation.
Why Proton Therapy Works Differently
Standard radiation uses X-ray beams that pass through the body, depositing energy along their entire path and continuing out the other side. Proton beams behave differently. They release most of their energy at a precise depth, in what physicists call the Bragg peak, then stop. There is virtually no radiation beyond that point. This means less dose reaches surrounding healthy tissue, which matters enormously when a tumor sits next to the brain, spinal cord, heart, or a child’s developing organs.
Brain and Skull Base Tumors
Tumors at the base of the skull are among the strongest candidates for proton therapy. Chordomas and chondrosarcomas grow in bone near the brainstem, optic nerves, and spinal cord. Delivering enough radiation to control these tumors with conventional beams risks serious neurological damage. Proton therapy can target these areas while sparing the structures millimeters away. In a study of pediatric spinal chordomas and chondrosarcomas treated with proton radiation after surgery, 20-year overall survival for conventional chordomas reached nearly 94%, with progression-free survival around 88%.
Other brain tumors covered by most insurers for proton therapy include glioblastomas, astrocytomas, meningiomas, craniopharyngiomas, acoustic neuromas, pineal gland tumors, and pituitary tumors. These are all situations where the tumor is embedded in or adjacent to critical brain structures, making the precision of the Bragg peak especially valuable.
Childhood Cancers
Children benefit from proton therapy more than almost any other patient group. A child’s body is still growing, and radiation that spills into healthy tissue can cause lifelong problems: stunted bone growth, hormonal deficiencies, learning difficulties, and a higher risk of developing a second cancer decades later. Proton therapy reduces the volume of normal tissue exposed to radiation, which directly lowers these long-term risks.
The pediatric cancers most commonly treated with protons include medulloblastoma, ependymoma, craniopharyngioma, low-grade glioma, retinoblastoma, neuroblastoma, and soft tissue or bone sarcomas of the head, neck, spine, and pelvis. Medulloblastoma is a particularly strong case for protons because treatment requires irradiating the entire brain and spinal cord. Proton beams eliminate the exit dose into the chest, abdomen, and pelvis that conventional radiation delivers, reducing both organ damage and the estimated risk of secondary cancers. Medicare and most major insurers recognize nearly all solid pediatric tumors as appropriate for proton therapy when treated with curative intent.
Eye Tumors
Uveal melanoma, the most common cancer originating inside the eye, is one of proton therapy’s longest-established success stories. Five-year local control rates exceed 90%, and that control holds at 10 and 15 years. Only 7 to 10% of patients ultimately need the eye removed. Many patients experience some decline in visual sharpness after treatment, but 60 to 70% retain purposeful vision. More recent, higher-volume treatment centers report even better visual outcomes as techniques have improved.
Head and Neck Cancers
Advanced or surgically unresectable head and neck cancers, including those of the paranasal sinuses, are well-established proton therapy candidates. The head and neck region is packed with structures that affect daily quality of life: salivary glands, swallowing muscles, the jaw, and the spinal cord. Conventional radiation to this area frequently causes severe chronic dry mouth, a condition called xerostomia that can permanently impair eating, speaking, and dental health.
A study comparing proton therapy to standard intensity-modulated radiation in oropharyngeal cancer patients found that moderate-to-severe xerostomia at 18 to 36 months was dramatically lower with protons: 6% versus 20%. That difference is meaningful in practical terms. Chronic dry mouth affects every meal, every conversation, and every night of sleep for years after treatment ends.
Liver Cancer
Hepatocellular carcinoma, the most common form of primary liver cancer, is a strong candidate for proton therapy because the liver is uniquely vulnerable to radiation damage. Many liver cancer patients already have compromised liver function from cirrhosis or hepatitis, so even modest radiation to healthy liver tissue can tip them into liver failure. Proton beams deposit their dose in the tumor and stop, dramatically reducing the radiation absorbed by the surrounding liver.
Dosimetric comparisons show proton therapy cuts the mean radiation dose to healthy liver tissue significantly compared to conventional techniques. In one comparison, the estimated risk of radiation-induced liver disease dropped from 22.3% with standard radiation to 2.3% with protons. This advantage also allows doctors to treat larger tumors, multifocal disease, and tumors involving blood vessels that might otherwise be considered too risky for radiation.
Spinal Tumors
Primary or metastatic tumors of the spine present a particular challenge because the spinal cord runs directly through or alongside the treatment area. The spinal cord has a strict lifetime radiation tolerance. Exceed it, and the patient risks paralysis. Proton therapy’s sharp dose falloff allows higher tumor doses while respecting the cord’s limits. This is especially important for patients who have already received spinal radiation and need retreatment.
Prostate Cancer
Prostate cancer is one of the more debated applications. Proton therapy is used for prostate cancer, but the advantage over modern conventional radiation is less clear-cut than for the cancers listed above. A comparative study of younger men with prostate cancer found that proton therapy patients had lower rates of urinary side effects at two years (33% versus 42%), with benefits across incontinence, bleeding, and obstruction. However, bowel toxicity was actually higher with protons (20% versus 15%), primarily from late rectal bleeding. The treatment also cost nearly twice as much. Many insurers classify prostate cancer in a second tier that requires additional justification for coverage.
Retroperitoneal Sarcomas
Soft tissue sarcomas that develop behind the abdominal organs, called retroperitoneal sarcomas, often grow to large sizes before detection. When these tumors cannot be completely removed surgically, radiation is used to improve local control. The challenge is that the kidneys, small intestine, liver, and spinal cord are all nearby. Proton therapy can deliver effective doses to these large, irregularly shaped tumors while reducing the radiation absorbed by surrounding abdominal organs.
Re-irradiation for Recurrent Cancers
One of proton therapy’s most compelling applications is treating cancers that come back in an area that has already been irradiated. Every organ has a cumulative radiation tolerance. Once a patient has received a full course of conventional radiation, retreating the same area risks devastating side effects to tissues already near their limits. Proton therapy’s lack of exit dose and tight dose distribution allow radiation oncologists to deliver potentially curative doses to recurrent tumors while staying within the tolerance of previously irradiated tissues.
This applies across multiple cancer types. Recurrent head and neck cancers at the skull base, recurrent rectal cancers in patients who received prior pelvic radiation, and recurrent gynecologic cancers are all scenarios where proton re-irradiation can offer a second chance at disease control. In recurrent rectal cancer, proton therapy has enabled delivery of high tumoricidal doses of 60 to 65 Gy when surgery is not possible, something that would be unsafe with conventional beams in a previously irradiated pelvis.
What Insurance Typically Covers
Most insurers, including Medicare, divide proton therapy indications into two groups. The first group includes cancers where proton therapy’s benefit is well established: pediatric tumors, skull base tumors, eye cancers, CNS tumors, head and neck cancers, liver cancer, spinal tumors, retroperitoneal sarcomas, and re-irradiation cases. Coverage for these is relatively straightforward. A second group covers other cancer types where the evidence is still accumulating. For these, insurers typically require the treating center to demonstrate experience with data collection and peer-reviewed publication. Prostate cancer, esophageal cancer, and lung cancer generally fall into this second category, and coverage decisions vary by insurer and individual clinical circumstances.